Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Chemotherapy drug resistance for breast cancer may be modified with dofequidar fumarate
March 16th, 2006
Chemotherapy drug resistance for breast cancer may be modified with dofequidar fumarate. "Recent developments with chemotherapy for breast cancer have improved patient survival. However, there continue to be nonresponders to conventional anticancer agents," noted researchers in Japan. T. Saeki and colleagues of the Saitama Medical School wrote, "Multidrug resistance (MDR) is caused by the expression of P-glycoprotein (P-gp) on the cell membrane. The expression of P-gp is encoded by MDR1 mRNA in tumors and is associated with clinical drug resistance. Since P-gp appears to be involved in both acquired and congenital MDR in human cancers, P-gp could be...
Source: Women's Health Weekly (2006-03-16)
|
